Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04483973 · ClinicalTrials.gov registry record · Phase 2
SPI-1005 Treatment in Severe COVID-19 Patients
A Phase 2 study, sponsored by Sound Pharmaceuticals, Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04483973: Completed Phase 2 study, sponsored by Sound Pharmaceuticals, Incorporated.
NCT04483973 is a Phase 2 study that has completed, run by Sound Pharmaceuticals, Incorporated. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04483973, a Phase 2 study, has completed, sponsored by Sound Pharmaceuticals, Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.
Primary Outcome
Number of participants with adverse events, categorized by Common Terminology Criteria for Adverse Events (CTCAE) grading for severity.
Interventions
- DRUG Placebo
- DRUG Ebselen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 2 |
What the finished NCT04483973 record still lists
NCT04483973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04483973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04483973 about?
NCT04483973 is a clinical study titled "SPI-1005 Treatment in Severe COVID-19 Patients". The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.
What is the current status of trial NCT04483973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-08-27. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT04483973?
The interventions under investigation include: Placebo (DRUG), Ebselen (DRUG).
Who is sponsoring clinical trial NCT04483973?
This trial is sponsored by Sound Pharmaceuticals, Incorporated, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04483973's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI